Cargando…
Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis
BACKGROUND: The primary objective was to demonstrate the safety and tolerability of monoclonal antibody against CD14 (IC14) (atibuclimab) in amyotrophic lateral sclerosis patients. The secondary objectives were pharmacokinetics, pharmacodynamics, and preliminary effects on disease status and biomark...
Autores principales: | Henderson, Robert D., Agosti, Jan M., McCombe, Pamela A., Thorpe, Kathryn, Heggie, Susan, Heshmat, Saman, Appleby, Mark W., Ziegelaar, Brian W., Crowe, David T., Redlich, Garry L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542123/ https://www.ncbi.nlm.nih.gov/pubmed/34678870 http://dx.doi.org/10.1097/MD.0000000000027421 |
Ejemplares similares
-
Research trends in chemogenetics for neuroscience in recent 14 years: A bibliometric study in CiteSpace
por: Chen, Yuerong, et al.
Publicado: (2023) -
Monocytes and neutrophils are associated with clinical features in amyotrophic lateral sclerosis
por: McGill, Raquel B, et al.
Publicado: (2020) -
Effect of Nusinersen in a late onset spinal muscular atrophy patient for 14 months: A case report
por: Park, Jin-Mo, et al.
Publicado: (2021) -
Effectiveness of dose-escalated topiramate monotherapy and add-on therapy in neurosurgery-related epilepsy: A prospective study
por: Liu, Yu-Tse, et al.
Publicado: (2020) -
Renal function in amyotrophic lateral sclerosis patients on long-term treatment with edaravone
por: Kakimoto, Asako, et al.
Publicado: (2021)